Sign up USA
Proactive Investors - Run By Investors For Investors

Pfizer tops Q4 hopes but lowers guidance for 2016

Revenue rose to US$14.05bn from US$13.1bn, also ahead of expectations of around US$13.6bn.
Pfizer tops Q4 hopes but lowers guidance for 2016
Pfizer is merging with Allergan

--- adds share price---

Pharma giant Pfizer (NYSE:PFE) beat expectations in its fourth quarter but tempered forecasts for the coming year.

The firm reported on Tuesday that fourth-quarter earnings halved compared to the previous year to US$61mln, or 10 cents per share (EPS), from US$1.22bn, or 19 cents per share.

However, the results include three months of legacy Hospira global operations, Pfizer said, and adjusted EPS was 53 cents per share, slightly ahead of hopes.

Revenue rose to US$14.05bn from US$13.1bn, also ahead of expectations of around US$13.6bn.

But for, 2016, the company said it expects "significant negative currency impact related to Venezuela."

Excluding the effects of its merger with Allergan, Pfizer said it expects adjusted EPS of US$2.20 to US$2.30, including the impact of currency headwinds, below estimates of US$2.38 per share.

Before the resumption of trading on Wall Street, shares were trading 1.7% lower in the pre-market trading, before nudging 0.77% higher in the regular session at US$30.21.

Jonny.jpg


Register here to be notified of future PFE Company articles
View full PFE profile

Pfizer Timeline

Article
November 23 2015

Related Articles

antibiotic.jpg
March 02 2016
In all 1,200 patients will take part in the global trials run by Motif’s partner Covance.
Cancer
March 31 2016
This broad coverage protects the company's lead immunotherapy, ImMucin
Diagnostic test
Thu
The timetable for the HCV test trials is relatively short
Copyright © Proactiveinvestors.com, 2016. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC